Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (DE:4XC1)
FRANKFURT:4XC1
RESEARCH TOOLSreports
Holding DE:4XC1?
Track your performance easily
4XC1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.30 - €20.20
Previous Close€9.5
Volume0.00
Average Volume (3M)N/A
Market Cap
€469.31M
Enterprise Value€309.08M
Total Cash (Recent Filing)$174.27M
Total Debt (Recent Filing)$6.25M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Dec 05, 2024EPS Estimate
-€0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,215,472
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
€24.16Price Target Upside154.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
KalVista Pharmaceuticals News
PremiumCompany Announcements
KalVista Pharmaceuticals Appoints Laurence Reid to Board
PremiumCompany Announcements
KalVista Pharmaceuticals Announces $60 Million Funding Initiatives
PremiumCompany Announcements
KalVista Secures $184M Financing for Sebetralstat Launch
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageSebetralstat will benefit from first to market advantage, if approved.
Drug ApprovalSebetralstat Ph3 data is highly supportive of an approval.
Market PotentialSebetralstat could fill this unmet need with a compelling efficacy and safety profile combined with the clear desire for convenient oral therapies.
Bears Say
CompetitionDeucrictibant is positioned as a potential competitor to sebetralstat.
Regulatory MilestonesStock remains flat despite significant achievements such as NDA filing.
Stock PerformanceStock has been flattish despite major milestones like phase III success.
---
4XC1 FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was €7.30 and its highest was €20.20 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
Currently, no data Available
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Dec 05, 2024 which is in 8 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Sep 05, 2024. The company reported -€0.83 earnings per share for the quarter, beating the consensus estimate of -€0.873 by €0.043.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -€0.87.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 48,715,473 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -€0.83 in its last earnings report, beating expectations of -€0.873. Following the earnings report the stock price went up 4.587%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Woodline Partners LP. It holds KalVista Pharmaceuticals’s shares valued at 7M.
---
KalVista Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.16 (154.27% Upside)
€24.16 (154.27% Upside)
Blogger Sentiment
Bullish
DE:4XC1 Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.45%
12-Months-Change
Fundamentals
Return on Equity
-90.84%
Trailing 12-Months
Asset Growth
24.86%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
4XC1 Stock 12 Month Forecast
Average Price Target
€24.16
▲(154.27% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Sangamo Biosciences
―
Omeros
―
Annovis Bio
―
KalVista Pharmaceuticals
―
Best Analysts Covering 4XC1
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+10.62%
reiterated a buy rating 23 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.62% per trade.
---